Climb Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLYM research report →
Range $17 – $35
Price Chart
About the company
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody.
- CEO
- Aoife Brennan BCh MMSc
- IPO
- 2021
- Employees
- 28
- HQ
- Wellesley Hills, MA, US
Get TickerSpark's AI analysis on CLYM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $974.62M
- P/E
- -20.51
- PEG
- 1.01
- P/S
- 0.00
- P/B
- 5.41
- EV/EBITDA
- -15.70
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -31.79%
- ROIC
- -26.89%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-97,000+0.0%
- Op Income
- $-67,883,000
- Net Income
- $-59,851,000+19.0%
- EPS
- $-0.88+42.5%
- OCF Growth
- -249.3%
- FCF Growth
- -250.5%
- 52W High
- $18.14
- 52W Low
- $1.54
- 50D MA
- $13.18
- 200D MA
- $7.96
- Beta
- 0.07
- RSI (14)
- 73
- Avg Volume
- 1.32M
No earnings-call transcripts are available for CLYM yet.
- Free Float
- 85.9%
- Shares Outstanding
- 57.26M
- Float Shares
- 49.20M
Buy/sell ratio 5.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 89 ETFs
Biggest fund positions in CLYM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 70,284 |
| Jun 29, 26 | Celebi Breanna Maurine | other | 70,284 |
| Jun 29, 26 | Celebi Breanna Maurine | other | 0 |
| Jun 27, 26 | Brennan Aoife | other | 68,750 |
| Jun 27, 26 | Brennan Aoife | other | 68,750 |
| Jun 29, 26 | Brennan Aoife | sell | 30,902 |
| Jun 5, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 40,000 |
| Jun 5, 26 | Levin Andrew David | other | 40,000 |
| Jun 5, 26 | Drapkin Kimberlee C | other | 40,000 |
| Jun 5, 26 | WILLIAMS DOUGLAS E | other | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLYM coverage
Recent articles, reports, and earnings notes.
No research on CLYM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLYM report →Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgrade
defenseworld.net · Jul 28
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade
defenseworld.net · Jul 28
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility
seekingalpha.com · Jul 23
Why Is Climb Bio Stock Gaining Friday?
benzinga.com · Jun 12
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
globenewswire.com · Jun 11
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
globenewswire.com · Jun 5
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
globenewswire.com · May 26
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
marketbeat.com · May 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.